Reviva Pharmaceuticals Holdings, Inc.
RVPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001742927
No open-market purchases or sales by Reviva Pharmaceuticals Holdings, Inc. insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $3.67K in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Reviva Pharmaceuticals Holdings, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −1 vs. Q4 2022
- Shares held
- 1.38M
- +72.1K (+5.5%) vs. Q4 2022
- Total value
- $5.76M
- +$222.0K (+4.0%) vs. Q4 2022
- New holders
- 4
- 4 more added
- Sold out
- 5
- 9 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RVPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 5 | $3.67K |
| Q1 2026 | 35 | $2.13M |
| Q4 2025 | 48 | $3.17M |
| Q3 2025 | 42 | $3.52M |
| Q2 2025 | 46 | $5.44M |
| Q1 2025 | 49 | $6.95M |
| Q4 2024 | 42 | $14.0M |
| Q3 2024 | 33 | $14.3M |
| Q2 2024 | 31 | $8.75M |
| Q1 2024 | 28 | $21.0M |
| Q4 2023 | 36 | $27.1M |
| Q3 2023 | 24 | $13.0M |
| Q2 2023 | 23 | $15.5M |
| Q1 2023 | 22 | $5.76M |
| Q4 2022 | 23 | $5.54M |
| Q3 2022 | 19 | $1.65M |
| Q2 2022 | 13 | $2.05M |
| Q1 2022 | 16 | $4.68M |
| Q4 2021 | 14 | $7.54M |
| Q3 2021 | 12 | $10.5M |
| Q2 2021 | 12 | $12.8M |
| Q1 2021 | 8 | $3.37M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Reviva Pharmaceuticals Holdings, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 1 | $4 | 0.00% | −33−97.1% | Reduced |
| Wells Fargo & Company | 110 | $461 | 0.00% | +1+0.9% | Added |
| Tower Research Capital LLC (TRC) | 1,519 | $6.00K | 0.00% | −8,518−84.9% | Reduced |
| Citadel Advisors LLC | 3,526 | $14.8K | 0.00% | +3,526 | New |
| Wolverine Asset Management LLC | 6,104 | $25.6K | 0.00% | −710−10.4% | Reduced |
| Belvedere Trading LLC | 6,359 | $26.6K | 0.01% | +6,359 | New |
| Northwestern Mutual Wealth Management Co | 9,299 | $39.0K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 12,236 | $51.3K | 0.00% | −16,986−58.1% | Reduced |
| Bank of New York Mellon Corp | 15,047 | $63.0K | 0.00% | +511+3.5% | Added |
| Two Sigma Investments, LP | 16,400 | $68.7K | 0.00% | −30,635−65.1% | Reduced |
| Renaissance Technologies LLC | 19,124 | $80.0K | 0.00% | −1,176−5.8% | Reduced |
| Northern Trust Corp | 27,115 | $113.6K | 0.00% | −4,138−13.2% | Reduced |
| Sabby Management, LLC | 28,610 | $119.9K | 0.45% | −5,890−17.1% | Reduced |
| Millennium Management LLC | 38,435 | $161.0K | 0.00% | +38,435 | New |
| State Street Corp | 44,400 | $186.0K | 0.00% | 00.0% | Unchanged |
| Tang Capital Management LLC | 53,200 | $222.9K | 0.03% | +29,075+120.5% | Added |
| Susquehanna International Group, LLP | 73,108 | $306.3K | 0.00% | −18,422−20.1% | Reduced |
| BlackRock Inc. | 84,954 | $356.0K | 0.00% | 00.0% | Unchanged |
| Colony Group LLC | 93,000 | $390.0K | 0.01% | +93,000 | New |
| EMC Capital Management | 123,915 | $517.0K | 0.43% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 145,430 | $609.4K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 573,770 | $2.40M | 0.00% | +107,353+23.0% | Added |
| XTX Topco Ltd | 0 | $0 | 0.00% | −58,475−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −38,600−100.0% | Sold out |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −12,232−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −10,303−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −12−100.0% | Sold out |